Rather & Kittrell Inc. bought a new position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,582 shares of the company stock, valued at approximately $ 270,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steward Financial Group LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $ 34,000. Jackson Wealth Management LLC increased its stake in Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock valued at $ 40,000 after purchasing an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock valued at $ 45,000 after purchasing an additional 61 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock valued at $ 47,000 after purchasing an additional 218 shares during the last quarter. Finally, Gibson Wealth Advisors LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at $ 49,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $ 12,336,803. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider William Hait sold 29,699 shares of the company stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares in the company, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,161 shares of company stock worth $ 13,895,302. Corporate insiders own 0.35% of the company stock.
JNJ has been the subject of several recent research reports. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Raymond James upped their price target on shares of Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $ 180.00 to $ 183.00 in a research report on Wednesday, March 16th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Finally, Credit Suisse Group upped their price target on shares of Johnson & Johnson from $ 200.00 to $ 205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Buy” and an average price target of $ 190.50.
Shares of NYSE JNJ opened at $ 169.99 on Thursday. Johnson & Johnson has a twelve month low of $ 155.72 and a twelve month high of $ 186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $ 447.31 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 3.41 and a beta of 0.66. The firm has a 50-day moving average of $ 178.59 and a two-hundred day moving average of $ 172.62.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company had revenue of $ 23.43 billion during the quarter, compared to the consensus estimate of $ 23.62 billion. During the same period in the prior year, the company earned $ 2.59 EPS. Johnson & Johnson’s revenue was up 5.0% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a dividend of $ 1.13 per share. This represents a $ 4.52 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s payout ratio is presently 60.92%.
About Johnson & Johnson: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also:
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.